Small Boost In Proposed NIH Budget Could Help Fund Electroceuticals Project
The National Institutes of Health would see only a slight, less than 1%, increase over 2014 in its fiscal year 2015 budget under the president’s spending plan, but part of the increase could advance so-called electroceuticals research, NIH director Francis Collins explained.
You may also be interested in...
By seeding exploratory lab work across several biomedical and engineering disciplines, pharma giant GlaxoSmithKline wants to understand how neural signals regulate diseases and eventually to design devices that can alter signals and provide therapeutic benefit.
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.